Measurement of the activated clotting time during cardiopulmonary bypass: Differences between Hemotec® ACT and Hemochron® Jr apparatus

Perfusion

Volumn 19, Issue 5, 2004, Pages 289-294

  Svenmarker, Staffan ^a   Appelblad, M ^a   Jansson, E ^a   Haggmark S ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

KAOLIN; PHOSPHOLIPID; SILICON DIOXIDE;

ACCURACY; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE VOLUME; EX VIVO STUDY; FEMALE; HEMODILUTION; HUMAN; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MALE; MEASUREMENT; MONITOR; PRIORITY JOURNAL; STANDARDIZATION;

AGED; BIAS (EPIDEMIOLOGY); CARDIOPULMONARY BYPASS; FEMALE; HEMODILUTION; HUMANS; INDICATORS AND REAGENTS; KAOLIN; MALE; PHOSPHOLIPIDS; REFERENCE STANDARDS; SILICON DIOXIDE; WHOLE BLOOD COAGULATION TIME;

EID: 5444229752     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659104pf755oa     Document Type: Article

References (20)

1. Shore Lesserson L, Gravlee GP. Anticoagulation for cardiopulmonary bypass. In Gravlee G, Davis R, Kurusz M, Utley JR eds. Cardiopulmonay bypass: principles and practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2000: 435-72.
2. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-40.
3. Bull BS, Huse WM, Brauer FS et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685-89.
4. Bull BS, Korpman RA, Huse WM et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69: 674-84.
5. Niinikoski J, Laato M, Laaksonen V et al. Use of activated clotting time to monitor anticoagulation during cardiac surgery. Scand J Thorac Cardiovasc Surg 1984; 18: 57-61.
6. Reich DL, Zahl K, Perucho MH et al. An evaluation of two activated clotting time monitors during cardiac surgery. J Clin Monit 1992; 8: 33-36.
7. Aylsworth CL, Stefan F, Woitas K et al. New technology, old standards: disparate activated clotting time measurements by the Hemochron Jr compared with the standard Hemochron. Ann Thorac Surg 2004; 77: 973-76.
8. Carter AJ, Hicks K, Heldman AW et al. Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques. Cathet Cardiovasc Diagn 1996; 39: 97-102.
9. Pan C-M, Jobes D, Van Riper D et al. Modified microsample ACT test for heparin monitoring. J Extra Corp Technol 1996; 28: 16-20.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
11. Hattersley PG. A semiautomated instrument for the activated coagulation time (ACT). Am J Clin Pathol 1980; 73: 293.
12. Culliford AT, Gitel SN, Starr N et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193: 105-11.
13. Hug MI, Di Bernardo S, Berger F et al. Measurement of activated clotting time in children - comparison of the Celite i-STAT ACT with the Medtronic ACT II. Acta Anaesthesiol Scand 2004; 48: 211-17.
14. Wendel HP, Heller W, Gallimore MJ et al. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993; 4: 41-45.
15. Kmiecik SA, Liu JL, Vaadia TS et al. Quantitative evaluation of hypothermia, hyperthermia, and hemodilution on coagulation. J Extra Corpor Technol 2001; 33: 100-105.
16. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984; 63: 394-98.
17. Koster A, Despotis G, Gruendel M et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg 2002; 95: 26-30.
18. Ottesen S, Frøysaker T. Use of Haemonetics Cell Saver for autotransfusion in cardiovascular surgery. Scand J Thorac Cardiovasc Surg 1982; 16: 263-68.
19. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-17.
20. Welsby IJ, McDonnell E, El-Moalem H et al. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput 2002; 17: 287-92.